Similarly, low-dose chemobiotherapy with temozolomide, GM-CSF, IFN-α2β, and recombinant IL-2 produced clinical responses in patients with metastatic melanoma and may protect against the development of brain metastases [111]. Here, IL2 is linked to metastatic melanoma.